When a patient’s HR or HER2 status is either unknown or not HR-positive and HER2-negative, the evidence level assigned to capivasertib for treating breast cancer is adjusted to Level C. Additionally, it may stem from the inclusion of drugs approved in China and recommended by the Chinese Society of Clinical Oncology (CSCO) guidelines (https://www.csco.org.cn/) in OKAIN, which are not listed in OncoKB, such as almonertinib. This evidence concerns the gene ERBB2 and breast carcinoma.